<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89228-0010 </DOCNO><DOCID>fr.2-28-89.f2.A1009</DOCID><TEXT><ITAG tagnum="94"><ITAG tagnum="69"><ITAG tagnum="50">DEPARTMENT OF HEALTH AND HUMAN SERVICES</ITAG><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="52">21 CFR Part 5</ITAG><ITAG tagnum="56">Delegations of Authority and Organization; Center for Biologics Evaluationand Research and Center for Drug Evaluation and Research, et al.</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Final rule.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is amending theregulations for delegations of authority relating to functions performedby the Center for Biologics Evaluation and Research (CBER), the Centerfor Drug Evaluation and Research (CDER), the Center for Devices and RadiologicalHealth (CDRH), and regional offices. This amendment updates the titlesof the delegates to conform to new organizational structures. The amendmentalso updates the delegation regarding approval of new drug applicationsand their supplements and removes the obsolete delegation regarding bioequivalencyrequirements.</ITAG><ITAG tagnum="10"><T2>EFFECTIVE DATE: </T2>February 28, 1989.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2>Melissa M. Moncavage, Office ofManagement and Operations (HFA-340), Food and Drug Administration, 5600Fishers Lane, Rockville, MD 20857, 301-443-4976.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>The Center for Drugs and Biologicswas reorganized into CBER and CDER. The center level structure was approvedby the Secretary of Health and Human Services and published in the <T4>Federal Register</T4> of October 15, 1987 (52 FR 38275). The officelevel structure was approved by the Assistant Secretary for Health andpublished March 18, 1988 (53 FR 8978). When the functional statements forCBER and CDER were published on October 15, 1987 and March 18, 1988, acontinuing delegation of authority was included in the reorganization topermit CBER and CDER officials to continue normal operations until thecenters' substructures were finalized. Most of the authorities delegatedto the center officials are amended in this document to reflect new titlesand organizational placement under the new organizations.This document revises the delegations of authority contained in 21 CFRPart 5 relating to the functions assigned to CBER and CDER. The affectedsections are the following:Section 5.22 <T3>Certification of true copies and use of Department seal </T3>(21 CFR5.22); andSection; 5.23 <T3>Disclosure of official records</T3> (21 CFR 5.23); andSection; 5.25 <T3>Research, investigation, and testing programs and health informationand health promotion programs</T3> (21 CFR 5.25); andSection; 5.26 <T3>Service fellowships </T3> (21 CFR 5.26); andSection; 5.30<T3> Hearings </T3>(21 CFR 5.30); andSection; 5.31 <T3>Petitions under Part 10 </T3>(21 CFR 5.31); andSection; 5.37 <T3>Issuance of reports of minor violations </T3>(21 CFR 5.37); andSection;5.44<T3> Export of unapproved drugs </T3>(21 CFR 5.44); andSection; 5.45<T3> Imports and exports </T3>(21 CFR 5.45); andSection; 5.47 <T3>Detention of adulterated or misbranded medical devices </T3>(21 CFR5.47); andSection; 5.49<T3> Authorization to use alternative evidence for determination of theeffectiveness of medical devices </T3>(21 CFR 5.49); andSection; 5.50 <T3>Notification to petitioners of determinations made on petitions forreclassification of medical devices </T3>(21 CFR 5.50); andSection; 5.52<T3>Notification to sponsors of deficiencies in petitions for reclassificationof medical devices </T3>(21 CFR 5.52); andSection; 5.53 <T3>Approval, disapproval, or withdrawal of approval of product developmentprotocols and applications for premarket approval for medical devices </T3>(21CFR 5.53); andSection; 5.54<T3> Determinations that medical devices present unreasonable risk of substantialharm </T3>(21 CFR 5.54); andSection; 5.55<T3> Orders to repair or replace, or make refunds for, medical devices</T3>(21 CFR 5.55); andSection; 5.58 <T3>Orphan products </T3>(21 CFR 5.58); andSection; 5.59 <T3>Approval, disapproval, or withdrawal of approval of applications forinvestigational device exemptions</T3> (21 CFR 5.59); andSection; 5.67 <T3>Issuance of notices of opportunity for a hearing on proposals for denialof approval of applications for licenses or revocation of licenses andcertain notices of revocation of licenses </T3>(21 CFR 5.67); andSection;5.68 <T3>Issuance and revocation of licenses for the propagation or manufactureand preparation of biological products </T3>(21 CFR 5.68); andSection; 5.69<T3> Notification of release for distribution of biological products </T3>(21CFR 5.69); andSection; 5.70 <T3>Issuance of notice implementing the provisions of the Drug Amendmentsof 1962 </T3>(21 CFR 5.70); andSection; 5.71 <T3>Termination of exemptions for new drugs for investigational use inhuman beings and in animals </T3>(21 CFR 5.71); andSection; 5.73 <T3>Certification of insulin </T3>(21 CFR 5.73); andSection; 5.74 <T3>Issuance, amendment, or repeal of regulations pertaining to drugs containinginsulin </T3>(21 CFR 5.74); andSection; 5.75 <T3>Designation of official master and working standards for antibioticdrugs </T3>(21 CFR 5.75); andSection; 5.76 <T3>Certification of antibiotic drugs </T3>(21 CFR 5.76); andSection; 5.78<T3>Issuance, amendment, or repeal of regulations pertaining to antibioticdrugs </T3>(21 CFR 5.78); andSection; 5.80 <T3>Approval of new drug applications and their supplements </T3>(21 CFR5.80); andSection; 5.82 <T3>Issuance of notices relating to proposals to refuse approval or towithdraw approval of new drug applications and their supplements</T3> (21CFR 5.82); andSection; 5.94 <T3>Extensions or stays of effective dates for compliance with certainlabeling requirements for human prescription drugs </T3>(21 CFR 5.94).In addition, FDA is changing titles in the sections listed above becauseof other reorganizations. In andSection;andSection; 5.22 and 5.26, FDA is changingthe Director, Office of Management and Systems, Center for Devices andRadiological Health (CDRH), to the Director, Office of Management Services,CDRH, to conform with the reorganization approved by the Director, Officeof Management, Public Health Service, and published in the <T4>Federal Register</T4> of March 3, 1987 (52 FR 6393). FDA is changingthe regional organization titles in andSection; 5.22 from Region II and RegionIV to Northeast Region and Southeast Region, respectively, to conform tothe new field structure approved by the Assistant Secretary for Healthand published in the <T4>Federal Register</T4> of July 2, 1987 (52 FR 25080).FDA is adding the Deputy Director, National Center for Toxicological Researchto the list of officials in andSection;andSection;5.25 and 5.26 to be consistentwith the other centers listed in the delegation. FDA is removing andSection;5.79 <T3>Issuance, amendment, or repeal of regulations establishing bioequivalencerequirements for drug products for human use </T3>(21 CFR 5.79) becausethe delegation is obsolete. Finally, FDA is amending andSection;5.80 <T3>Approval of new drug applications and their supplements </T3>(21 CFR5.80) to define accurately the types of drugs that are not considered newmolecular entities. Further redelegation of the authority delegated is not authorized. Authoritydelegated to a position by title may be exercised by a person officiallydesignated to serve in such position in an acting capacity or on a temporarybasis. <ITAG tagnum="84">List of Subjects in 21 CFR Part 5 </ITAG>Authority delegations (Government agencies), Imports, Organization andfunctions (Government agencies).Therefore, under the Federal Food, Drug, and Cosmetic Act and under authoritydelegated to the Commissioner of Food and Drugs, Part 5 is amended as follows:<ITAG tagnum="52">PART 5_DELEGATIONS OF AUTHORITY AND ORGANIZATION </ITAG>1. The authority citation for 21 CFR Part 5 continues to read as follows:<ITAG tagnum="21"><T4>Authority: </T4>5 U.S.C. 504, 552; 7 U.S.C. 2217; 15 U.S.C. 638, 1451<T3>et seq., </T3>3701 <T3>et seq.; </T3>21 U.S.C. 41 <T3>et seq., </T3>61-63, 141 <T3>et seq., </T3>301-392, 467f(b), 679(b), 801 <T3>et seq., </T3>823(f), 1031 <T3>et seq.; </T3>35 U.S.C. 156; 42 U.S.C. 219, 241, 242(a), 242a, 242l,242o, 243, 262, 263, 263b through 263m, 264, 265, 300u <T3>et seq., </T3>1395y and 1395y note, 3246b(b)(3), 4831(a), 10007, and10008; Federal Caustic Poison Act (44 Stat. 1406); Federal Advisory CommitteeAct (Pub. L. 92-463); E.O. 11490, 11921, 12591.</ITAG>2. Section 5.22 is amended by revising paragraphs (a)(7) (i) through (v),by removing paragraph (a)(7)(vi), by revising paragraph (a)(9)(ii), byredesignating paragraph (a)(12) as paragraph (a)(13), by adding new paragraph(a)(12), and by revising redesignated paragraphs (a)(13)(v) and (a)(13)(vi)to read as follows: <ITAG tagnum="80">andSection;5.22 </ITAG><ITAG tagnum="89">Certification of true copies and use of Department seal. </ITAG>(a) * * * (7)(i) The Director and Deputy Director, Center for Biologics Evaluationand Research (CBER). (ii) The Director, Office of Management, CBER. (iii) The Directors and Deputy Directors of the Offices of Compliance,Biological Product Review and Biologics Research, CBER. (iv) The Chiefs of the Case Management Staff and the Inspections and SurveillanceStaff, Regulations and Bioresearch Monitoring Staff, Office of Compliance,CBER. (v) The Chief, Biologics Information Staff, Office of Biological ProductReview, CBER. <ITAG tagnum="37">* * * * * </ITAG>(9) * * * (ii) The Director, Office of Management Services, CDRH. <ITAG tagnum="37">* * * * * </ITAG>(12)(i) The Director and Deputy Director, Center for Drug Evaluation andResearch (CDER). (ii) The Directors and Deputy Directors of the Offices of Management, Epidemiologyand Biostatistics, Compliance, Drug Evaluation I, Drug Evaluation II, DrugStandards, and Research Resources, CDER. (iii) The Chief, Freedom of Information Staff and Freedom of InformationOfficers, Office of Management, CDER. (iv) The Directors of the Division of Drug Labeling Compliance, Drug QualityEvaluation, and Manufacturing and Product Quality, Office of Compliance,CDER. (13) * * * (v) The Director, New York Laboratory Division, Northeast Region. (vi) The Director, Science Division, Southeast Region. <ITAG tagnum="37">* * * * * </ITAG>3. Section 5.23 is amended by revising paragraphs (b) and (e) to read asfollows: <ITAG tagnum="80">andSection;5.23 </ITAG><ITAG tagnum="89">Disclosure of official records. </ITAG><ITAG tagnum="37">* * * * * </ITAG>(b) The Chief, Drug Listing Branch, Division of Drug Labeling Compliance,Office of Compliance, Center for Drug Evaluation and Research (CDER), isauthorized to sign affidavits regarding the presence or absence of recordsof Registration of Drug Establishments. <ITAG tagnum="37">* * * * * </ITAG>(e) The Director and Deputy Director, Division of Product Certification,Office of Biological Product Review, Center for Biologics Evaluation andResearch, are authorized to sign affidavits regarding the presence or absenceof records of registration of blood product establishments. 4. Section 5.25 is amended by revising paragraphs (a)(1) and (a)(3) andby adding a new paragraph (a)(6) to read as follows: <ITAG tagnum="80">andSection;5.25 </ITAG><ITAG tagnum="89">Research, investigation, and testing programs and health informationand health promotion programs. </ITAG>(a) * * * (1) The Director and Deputy Director, National Center for ToxicologicalResearch. <ITAG tagnum="37">* * * * * </ITAG>(3) The Director and Deputy Director, Center for Biologics Evaluation andResearch. <ITAG tagnum="37">* * * * * </ITAG>(6) The Director and Deputy Director, Center for Drug Evaluation and Research.<ITAG tagnum="37">* * * * * </ITAG>5. Section 5.26 is amended by revising the section heading and paragraphs(b), (c), and (d), by redesignating paragraph (g) as paragraph (h), andby adding a new paragraph (g) to read as follows:<ITAG tagnum="80">andSection; 5.26</ITAG><ITAG tagnum="89">Service fellowships.</ITAG><ITAG tagnum="37">* * * * *      </ITAG>(b) The Director and Deputy Director, National Center for ToxicologicalResearch (NCTR), and the Director, Office of Management, NCTR.     (c) The Director and Deptuy Director, Center for Devices and RadiologicalHealth (CDRH), and the Director, Office of Management Services, CDRH.    (d) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER), and the Director, Office of Mangement, CBER.<ITAG tagnum="37">* * * * *      </ITAG>(g) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER), and the Director and Deputy Director, Office of Management, CDER.<ITAG tagnum="37">* * * * *    </ITAG>6. Section 5.30 is amended by revising paragraph (a)(2), by redesignatingparagraphs (a)(5) through (a)(7) as paragraphs (a)(6) through (a)(8), byadding new paragraph (a)(5), by revising paragraph (c)(3), by redesignatingparagraphs (c)(6) through (c)(9) as paragraphs (c)(7) through (c)(10),and by adding new paragraph (c)(6) to read as follows:<ITAG tagnum="80">andSection; 5.30</ITAG><ITAG tagnum="89">Hearings.     </ITAG>(a) * * *     (2) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER), and the Directors and Deputy Directors of the Offices of Drug EvaluationI, Drug Evaluation II, and Compliance, CDER.<ITAG tagnum="37">* * * * *      </ITAG>(5) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER), and the Directors and Deputy Directors of the Officesof Biological Product Review, Biologics Research, and Compliance, CBER.<ITAG tagnum="37">* * * * *      </ITAG>(c) * * *     (3) The Director and Deputy Director, CDER, and the Directors and DeputyDirectors of the Offices of Drug Evaluation I, Drug Evaluation II, andCompliance.<ITAG tagnum="37">* * * * *      </ITAG>(6) The Director and Deputy Director, CBER, and the Directors and DeputyDirectors of the Offices of Biological Product Review, Biologics Research,and Compliance, CBER.<ITAG tagnum="37">* * * * *     </ITAG>7. Section 5.31 is amended by revising paragraphs (a), (b)(1), (b)(2),(b)(3), (c)(1), (d)(1), (d)(2), and (e)(3), by adding a new paragraph (e)(4),by revising paragraphs (f)(1) through (f)(5), and by adding a new paragraph(f)(6) to read as follows:<ITAG tagnum="80">andSection; 5.31 </ITAG><ITAG tagnum="89">Petitions under Part 10.     </ITAG>(a) For drugs assigned to their organizations, the following officialsare authorized to grant or deny citizen petitions submitted under andSection;10.30 of this chapter for a stay of an effective date in andSection; 201.59of this chapter for compliance with certain labeling requirements for humanprescription drugs.     (1)(i) The Director and Deputy Director, Center for Biologics Evaluationand Research (CBER).     (ii) The Directors and Deputy Directors of the Offices of Biological ProductReview and Biologics Research, CBER.     (iii) The Directors and Deputy Directors of the divisions in the Officesof Biological Product Review and Biologics Research, CBER.     (2)(i) The Director and Deputy Director, Center for Drug Evaluation andResearch (CDER).     (ii) The Directors and Deputy Directors of the Offices of Drug EvaluationI and Drug Evaluation II, CDER.     (iii) The Directors and Deputy Directors of the divisions in the Officesof Drug Evaluation I and Drug Evaluation II, CDER.     (b) * * *     (1) The Director and Deputy Director, CDER.     (2) The Director and Deputy Director, Office of Drug Standards, CDER.    (3) The Director and Deputy Director, Division of OTC Drug Evaluation,Office of Drug Standards, CDER.     (c) * * *     (1) The Director and Deputy Director, CDER, and the Director and DeputyDirector, Office of Complince, CDER.<ITAG tagnum="37">* * * * *      </ITAG>(d) * * *     (1) The Director and Deputy Director, CDER.     (2) The Director and Deputy Director, Office of Drug Standards, CDER.    (e) * * *     (3) The Director and Deputy Director, CBER, are authorized to issue 180-daytentative responses to citizen petitions on biological product mattersunder andSection; 10.30(e)(2)(iii) of this chapter that relate to the assignedfunctions of that Center.     (4) The Director and Deputy Director, CDER, are authorized to issue 180-daytentative responses to citizen petitions on drug product matters underandSection; 10.30(e)(2)(iii) of this chapter that relate to the assignedfunctions of that Center.     (f)(1) The Director and Deputy Director, CBER, are authorized to grantor deny citizen petitions submitted under andSection; 10.30 of this chapteron drug and biological product matters in program areas where they havebeen delegated final approval authority in the following sections of thispart:     (i) Section 5.68 <T3>Issuance and revocation of licenses for the propagation or manufactureand preparation of biological products</T3>;          (ii) Section 5.69 <T3>Notification of release for distribution of biological products;</T3>(iii) Section 5.71 <T3>Termination of exemptions for new drugs for investigational use inhuman beings or in animals;</T3>(iv) Section 5.80 <T3>Approval of new drug applications and their supplements; </T3>and(v) Section 5.82 <T3>Issuance of notices relating to proposals to refuse approval or towithdraw approval of new drug applications and their supplements.</T3>(2) The Director and Deputy Director, CDER, are authorized to grant ordeny citizen petitions submitted under andSection; 10.30 of this chapteron drug product matters in program areas where they have been delegatedfinal approval authority in the following sections of this part:(i) Section 5.70 <T3>Issuance of notices implementing the provisions of the Drug Amendmentsof 1962 (DESI);</T3>(ii) Section 5.71 <T3>Termination of exemptions for new drugs for investigational use inhuman beings or in animals;</T3>(iii) Section 5.73 <T3>Certification of insulin;</T3>(iv) Section 5.74 <T3>Issuance, amendment, or repeal of regulations pertaining to drugs containinginsulin;</T3>(v) Section 5.75 <T3>Designation of official master and working standards for antibioticdrugs;</T3>(vi) Section 5.76 <T3>Certification of antibiotic drugs;</T3>(vii) Section 5.78 <T3>Issuance, amendment, or repeal of regulations pertaining to antibioticdrugs;</T3>(viii) Section 5.80 <T3>Approval of new drug applications and their supplements;</T3> and(ix) Section 5.82 <T3>Issuance of notices relating to proposals to refuse aproval or to withdrawapproval of new drug applications and their supplements.</T3>(3) The Director and Deputy Director, Office of Drug Standards, CDER, exceptfor those drug products listed in andSection; 314.440(b) of this chapter,are authorized to issue responses to citizen petitions submitted underandSection; 10.30 of this chapter seeking a determination of the suitabilityof an abbreviated new drug application for a drug product.(4) The Director and Deputy Director, Office of Biological Product Review,CBER, for those drug products listed in andSection; 314.440(b) of this chapter,are authorized to issue responses to citizen petitions submitted underandSection; 10.30 of this chapter seeking a determination of the suitabilityof an abbreviated new drug application for a drug product.(5) For drugs assigned to their organization, the following officials areauthorized to issue responses to citizen petitions submitted under andSection;10.30 of this chapter from sponsors of an investigational new drug applicationwho request approval to ship in interstate commerce, in accordance withandSection; 2.125(j) of this chapter, an investigational new drug for humanuse containing a chlorofluorocarbon.(i) The Director and Deputy Director, CBER.(ii) The Director and Deputy Director, CDER.(6) The Director and Deputy Director, CVM, are authorized to issue responsesto citizen petitions submitted under andSection; 10.30 of this chapter fromsponsors of an investigational new animal drug application who requestapproval to ship in interstate commerce, in accordance with andSection; 21.125(j)of this chapter, an investigational new animal drug for animal use containinga chlorofluorocarbon.<ITAG tagnum="37">* * * * *</ITAG>8. Section 5.37 is amended by revising paragraph (a)(1), by redesignatingparagraph (a)(5) as paragraph (a)(6), and by adding a new paragraph (a)(5)to read as follows:<ITAG tagnum="80">andSection; 5.37 </ITAG><ITAG tagnum="89">Issuance of reports of minor violations.</ITAG>(a) * * *(1)(i) The Director and Deputy Director, Center for Biologics Evaluationand Research (CBER).(ii) The Director and Deputy Director, Office of Compliance, CBER.<ITAG tagnum="37">* * * * *</ITAG>(5)(i) The Director and Deputy Director, Center for Drug Evaluation andResarch (CDER).(ii) The Director and Deputy Director, Office of Compliance, CDER.<ITAG tagnum="37">* * * * *</ITAG>9. Section 5.44 is amended by revising paragraphs (a)(1)(i) and (a)(1)(ii),by adding new paragraphs (a)(1)(iii) and (a)(1)(iv), by revising paragraphs(b)(1)(i) through (b)(1)(iv), by revising paragraphs (c)(1) and (c)(2),and by removing paragraph (c)(3) to read as follows:<ITAG tagnum="80">andSection; 5.44 </ITAG><ITAG tagnum="89">Export of unapproved drugs.</ITAG>(a) * * *(1) * * *(i) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER).(ii) The Director and Deputy Director, Office of Compliance, CBER.(iii) The Director and Deputy Director, Center for Drug Evaluation andResearch (CDER).(iv) The Director and Deputy Director, Office of Compliance, CDER.<ITAG tagnum="37">* * * * *</ITAG>(b) * * *(1) * * *(i) The Director and Deputy Director, CBER.(ii) The Director and Deputy Director, Office of Compliance, CBER.(iii) The Director and Deputy Director, CDER.(iv) The Director and Deputy Director, Office of Compliance, CDER.<ITAG tagnum="37">* * * * *</ITAG>(c) * * *(1) The Director and Deputy Director, CBER.(2) The Director and Deputy Director, Office of Compliance, CBER.10. Section 5.45 is amended by revising paragraphs (e)(1)(iii) and (e)(1)(iv)to read as follows:<ITAG tagnum="80">andSection; 5.45 </ITAG><ITAG tagnum="89">Imports and exports.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(e) * * *(1) * * *(iii) The Director and Deputy Director, Center for Biologics Evaluationand Research (CBER).(iv) The Director and Deputy Director, Office of Compliance, CBER.<ITAG tagnum="37">* * * * *</ITAG>11. Section 5.47 is amended by revising paragraphs (a)(3) and (4) to readas follows:<ITAG tagnum="80">andSection; 5.47 </ITAG><ITAG tagnum="89">Detention of adulterated or misbranded medical devices.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(a) * * *(3) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER).(4) The Director and Deputy Director, Office of Compliance, CBER.<ITAG tagnum="37">* * * * *</ITAG>12. Section 5.49 is amended by revising paragraph (b) to read as follows:<ITAG tagnum="80">andSection; 5.49 </ITAG><ITAG tagnum="89">Authorization to use alternative evidence for determination of theeffectiveness of medical devices.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(b) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER), and the Director and Deputy Director, Office of BiologicalProduct Review, CBER.13. Section 5.50 is amended by revising paragraph (b) to read as follows:<ITAG tagnum="80">andSection; 5.50 </ITAG><ITAG tagnum="89">Notification of petitioners of determinations made on petitions forreclassification of medical devices.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(b) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER), and the Director and Deputy Director, Office of BiologicalProduct Review, CBER.14. Section 5.52 is amended by revising paragraph (b) to read as follows:<ITAG tagnum="80">andSection; 5.52 </ITAG><ITAG tagnum="89">Notification to sponsors of deficiencies in petitions for reclassificationof medical devices.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(b) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER), and the Director and Deputy Director, Office of BiologicalProduct Review, CBER.15. Section 5.53 is amended by revising paragraphs (a)(2) and (b)(1)(ii)to read as follows:<ITAG tagnum="80">andSection; 5.53 </ITAG><ITAG tagnum="89">Approval, disapproval, or withdrawal of approval of product developmentprotocols and applications for premarket approval for medical devices.</ITAG>(a) * * *(2) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER), and the Director and Deputy Director, Office of BiologicalProduct Review, CBER.(b)(1) * * *(ii) The Director and Deputy Director, CBER, and the Director and DeputyDirector, Office of Biological Product Review, CBER.<ITAG tagnum="37">* * * * *</ITAG>16. Section 5.54 is amended by revising paragraph (b) to read as follows:<ITAG tagnum="80">andSection; 5.54 </ITAG><ITAG tagnum="89">Determinations that medical devices present unreasonable risk of substantialharm.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(b) The Director and Deputy Director, Center for Biologics Evaluation andResearch.17. Section 5.55 is amended by revising paragraph (b) to read as follows:<ITAG tagnum="80">andSection; 5.55 </ITAG><ITAG tagnum="89">Orders to repair or replace, or make refunds for, medical devices.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(b) The Director and Deputy Director, Center for Biologics Evaluation andResearch.18. Section 5.58 is amended by revising paragraphs (c)(1) and (c)(2), andby removing paragraph (c)(3) to read as follows:<ITAG tagnum="80">andSection; 5.58 </ITAG><ITAG tagnum="89">Orphan products.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(c) * * *(1) For drugs under their jurisdiction:(i) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(ii) The Directors and Deputy Directors of the Offices of Drug EvaluationI and Drug Evaluation II, CDER.(iii) The Division Directors of the divisions in the Offices of Drug EvaluationI and Drug Evaluation II, CDER.(2) For biological products under their jurisdiction:(i) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER).(ii) The Director and Deputy Director, Office of Biological Product Review,CBER.(iii) The Directors and Deputy Directors of the divisions in the Officeof Biological Product Review, CBER.19. Section 5.59 is amended by revising paragraph (a)(2) to read as follows:<ITAG tagnum="80">andSection; 5.59</ITAG><ITAG tagnum="89">Approval, disapproval, or withdrawal of approval of applications forinvestigational device exemptions.</ITAG>(a) * * *(2) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER), and the Director and Deputy Director, Office of BiologicalProduct Review, CBER.<ITAG tagnum="37">* * * * *</ITAG>20. Section 5.67 is amended by revising the introductory paragraph to readas follows:<ITAG tagnum="80">andSection; 5.67</ITAG><ITAG tagnum="89">Issuance of notices of opportunity for a hearing on proposals fordenial of approval of applications for licenses or revocation of licensesand certain notices of revocation of licenses.</ITAG>The Director and Deputy Director, Center for Biologics Evaluation and Researchare authorized to issue:<ITAG tagnum="37">* * * * *</ITAG>21. Section 5.68 is amended by revising the section heading and paragraphs(a) and (b) to read as follows:<ITAG tagnum="80">andSection; 5.68</ITAG><ITAG tagnum="89">Issuance and revocation of licenses for the propagation or manufactureand preparation of biological products.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(a) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER).(b) The Director and Deputy Director, Office of Biological Product Review,CBER.22. Section 5.69 is amended by revising paragraphs (a), (b), and (c) toread as follows:<ITAG tagnum="80">andSection; 5.69</ITAG><ITAG tagnum="89">Notification of release for distribution of biological products.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(a) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER).(b) The Director and Deputy Director, Office of Biological Product Review,CBER.(c) The Director and Deputy Director, Division of Product Quality Control,Office of Biological Product Review, CBER.23. Section 5.70 is revised to read as follows:<ITAG tagnum="80">andSection; 5.70</ITAG><ITAG tagnum="89">Issuance of notice implementing the provisions of the Drug Amendmentsof 1962.</ITAG>The Director and Deputy Director, Center for Drug Evaluation and Research,are authorized to issue notices and amendments thereto implementing section107(c)(3) of the Drug Amendments of 1962 (Pub. L. 87-781) by announcingnew or revised efficacy findings on human drugs that are or were subjectto the provisions of sections 505 and 507 of the Federal Food, Drug, andCosmetic Act.24. Section 5.71 is amended by revising paragraph (a), by redesignatingparagraph (b) as paragraph (d), by adding a new paragraph (b), and by addinga new paragraph (c) to read as follows:<ITAG tagnum="80">andSection; 5.71</ITAG><ITAG tagnum="89">Termination of exemptions for new drugs for investigational use inhuman beings and in animals.</ITAG>(a) The following officials, for drugs under their jurisdiction, are authorizedto perform all the functions of the Commissioner of Food and Drugs on thetermination of exemptions for new drugs (including those that are biologicalproducts which are subject to the licensing provisions of the Public HealthService Act) for investigational use in human beings under andSection; 312.44of this chapter and in animals under andSection; 312.160 of this chapter:(1) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER).(2) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(b) The following officials, for drugs under their jurisdiction, are authorizedto terminate exemptions for new drugs for investigational use when sponsorsfail to submit an annual progress report under andSection; 312.44(b)(1)(viii)of this chapter:(1) The Directors and Deputy Directors of the Offices of Drug EvaluationI and Drug Evaluation II, CDER.(2) The Directors and Deputy Directors of the divisions in the Officesof Drug Evaluation I and Drug Evaluation II, CDER.(3) The Director and Deputy Director, Office of Biological Product Review,CBER.(4) The Director and Deputy Director, Division of Biological InvestigationalNew Drugs, Office of Biological Product Review.(c) The following officials, for drugs under their jurisdiction, are authorizedto make the findings set forth in andSection; 312.44(b) of this chapter andto notify sponsors and invite correction before termination action on suchexemptions:(1) The Directors and Deputy Directors of the Offices of Drug EvaluationI and Drug Evaluation II, CDER.(2) The Directors and Deputy Directors of the divisions in the Officesof Drug Evaluation I and Drug Evaluation II, CDER.(3) The Director and Deputy Director, Office of Biological Product Review,CBER.(4) The Director and Deputy Director, Division of Biological InvestigationalNew Drugs, Office of Biological Product Review.<ITAG tagnum="37">* * * * *</ITAG>25. Section 5.73 is amended by revising paragraphs (a), (b), (c), and (d)to read as follows:<ITAG tagnum="80">andSection; 5.73</ITAG><ITAG tagnum="89">Certification of insulin.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(a) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(b) The Director and Deputy Director, Office of Compliance, CDER.(c) The Director and Deputy Director, Division of Drug Quality Evaluation,Office of Compliance, CDER.(d) The Chief and Assistant Chief, Product Surveillance Branch, Divisionof Drug Quality Evaluation, Office of Compliance, CDER.26. Section 5.74 is amended by revising paragraphs (a) and (b) to readas follows:<ITAG tagnum="80">andSection; 5.74</ITAG><ITAG tagnum="89">Issuance, amendment, or repeal of regulations pertaining to drugscontaining insulin.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(a) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(b) The Director and Deputy Director, Office of Compliance, CDER.27. Section 5.75 is amended by revising paragraphs (a), (b), and (c) toread as follows:<ITAG tagnum="80">andSection; 5.75</ITAG><ITAG tagnum="89">Designation of official master and working standards for antibioticdrugs.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(a) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(b) The Director and Deputy Director, Office of Research Resources, CDER.(c) The Director and Deputy Director, Division of Research and Testing,Office of Research Resources, CDER.28. Section 5.76 is amended by revising paragraphs (a), (b), (c), and (d)to read as follows:<ITAG tagnum="80">andSection; 5.76</ITAG><ITAG tagnum="89">Certification of antibiotic drugs.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(a) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(b) The Director and Deputy Director, Office of Compliance, CDER.(c) The Director and Deputy Director, Division of Drug Quality Evaluation,Office of Compliance, CDER.(d) The Chief and Assistant Chief, Product Surveillance Branch, Divisionof Drug Quality Evaluation, Office of Compliance, CDER.29. Section 5.78 is amended by revising paragraphs (a)(1) and (a)(2) toread as follows:<ITAG tagnum="80">andSection; 5.78</ITAG><ITAG tagnum="89">Issuance, amendment, or repeal of regulations pertaining to antibioticdrugs.</ITAG>(a) * * *(1) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(2) The Director and Deputy Director, Office of Compliance, CDER.<ITAG tagnum="37">* * * * *</ITAG><ITAG tagnum="80">andSection; 5.79</ITAG><ITAG tagnum="89">[Removed]</ITAG>30. Section 5.79 <T3>Issuance, amendment or repeal of regulations establishing bioequivalencerequirements for drug products for human use</T3> is removed.31. Section 5.80 is amended by removing the introductory paragraph, andby revising paragraphs (a), (b), (c)(1)(i), (c)(1)(ii), (c)(2)(ii), (d)(1),and (d)(2) to read as follows:<ITAG tagnum="80">andSection; 5.80</ITAG><ITAG tagnum="89">Approval of new drug applications and their supplements.</ITAG>(a)(1) The following officials are authorized to perform all the functionsof the Commissioner of Food and Drugs with regard to approval of new drugapplications and supplements thereto on drugs for human use, except forthose drugs listed in andSection; 314.440(b) of this chapter, that have beensubmitted under section 505 of the Federal Food, Drug, and Cosmetic Act:(i) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(ii) The Directors and Deputy Directors of the Offices of Drug EvaluationI and Drug Evaluation II, CDER, for drugs under their jurisdiction.(2) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER), for drugs listed in andSection; 314.440(b) of this chapter,are authorized to perform all the functions of the Commissioner of Foodand Drugs with regard to approval of new drug applications and supplementsthereto on drugs for human use that have been submitted under section 505of the Federal Food, Drug, and Cosmetic Act.(b) The officials listed in paragraphs (b) (1) and (2) of this section,for drugs under their jurisdiction, are authorized to perform all functionsof the Commissioner of Food and Drugs with regard to approval of supplementalapplications to approved new drug applications for drugs for human usethat have been submitted under andSection; 314.70 of this chapter and ofnew drug applications for drug products other than those that contain newmolecular entities (new chemical entities). The applications to which thisauthorization applies may, in appropriate circumstances, continue to beacted upon by the officials so authorized in andSection; 5.10(a) and paragraph(a) of this section.(1) The Directors and Deputy Directors of the divisions in the Office ofDrug Evaluation I, CDER.(2) The Directors and Deputy Directors of the divisions in the Office ofDrug Evaluation II, CDER.(c) * * *(1) * * *(i) The Director and Deputy Director, Office of Drug Standards, CDER.(ii) The Director and Deputy Director, Division of Generic Drugs, Officeof Drug Standards, CDER.(2)(i) * * *(ii) The Director and Deputy Director, Office of Biological Product Review,CBER.(d) * * *(1) The supervisory chemists in the divisions in the Office of Drug EvaluationI, CDER.(2) The supervisory chemists in the divisions in the Office of Drug EvaluationII, CDER.32. Section 5.82 is revised to read as follows:<ITAG tagnum="80">andSection; 5.82</ITAG><ITAG tagnum="89">Issuance of notices relating to proposals to refuse approval or towithdraw approval of new drug applications and their supplements.</ITAG>(a) The Director and Deputy Director, Center for Drug Evaluation and Research,are authorized to issue notices of an opportunity for a hearing on proposalsto refuse approval or to withdraw approval of new drug applications andabbreviated new drug applications and supplements thereto on drugs forhuman use, except for those drugs listed in andSection; 314.440(b) of thischapter, that have been submitted under section 505 of the Federal Food,Drug, and Cosmetic Act and Subpart B of Part 314 of this chapter and toissue notices refusing approval or withdrawing approval when opportunityfor hearing has been waived.(b) The Director and Deputy Director, Center for Biologics Evaluation andResearch, for those drugs listed in andSection; 314.440(b) of this chapter,are authorized to issue notices of an opportunity for a hearing on proposalsto refuse approval or to withdraw approval of new drug applications andabbreviated new drug applications and supplements thereto on drugs forhuman use that have been submitted under section 505 of the Federal Food,Drug, and Cosmetic Act and Subpart B of Part 314 of this chapter and toissue notices refusing approval or withdrawing approval when opportunityfor hearing has been waived. 33. Section 5.94 is amended by revising paragraphs (a) and (b), and byremoving paragraph (c) to read as follows:<ITAG tagnum="80">andSection; 5.94</ITAG><ITAG tagnum="89">Extensions or stays of effective dates for compliance with certainlabeling requirements for human prescription drugs.</ITAG><ITAG tagnum="37">* * * * *</ITAG>(a) For drugs assigned to their organizations:(1) The Director and Deputy Director, Center for Biologics Evaluation andResearch (CBER).(2) The Director and Deputy Director, Office of Biological Product Review,CBER.(3) The Directors and Deputy Directors of the divisions in the Office ofBiological Product Review, CBER.(b) For drugs assigned to their organizations:(1) The Director and Deputy Director, Center for Drug Evaluation and Research(CDER).(2) The Directors and Deputy Directors of the Office of Drug EvaluationI and Drug Evaluation II, CDER.(3) The Directors and Deputy Directors of the divisions in the Office ofDrug Evaluation I and Drug Evaluation II, CDER.<ITAG tagnum="21">Dated: February 21, 1989.</ITAG><ITAG tagnum="6">John M. Taylor,</ITAG><ITAG tagnum="4">Associate Commissioner for Regulatory Affairs.</ITAG><ITAG tagnum="40">[FR Doc. 89-4516 Filed 2-27-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></ITAG></TEXT></DOC>